Toradol (Ketorolac) Intramuscular Dosing
For adults, administer ketorolac 60 mg IM as a single loading dose, followed by 30 mg IM every 6 hours, with a maximum of 120 mg per day after the first day, and limit treatment to 5 days maximum. 1
Standard Adult Dosing
The recommended intramuscular regimen is:
- Loading dose: 30-60 mg IM initially
- Maintenance: 15-30 mg IM every 6 hours
- First day maximum: 150 mg
- Subsequent days maximum: 120 mg per day
- Duration limit: 5 days maximum 1, 2
Dose Adjustments for Special Populations
Elderly Patients (≥65 years)
Reduce the dose by 50% in patients aged 65 years or older. The recommended dosing is:
The rationale is that elderly patients demonstrate prolonged elimination half-life (increasing from 4.5 hours to 7.0 hours) and reduced total plasma clearance compared to younger adults 3. While considerable overlap exists between age groups, the elderly require less frequent dosing to maintain similar plasma levels and avoid accumulation 3.
Patients with Renal Impairment
Use the lower dose range (15 mg IM every 6 hours) for patients with impaired kidney function. 1, 2 Ketorolac is contraindicated in patients with advanced renal impairment or those at risk for renal failure 4.
Patients Weighing <50 kg
Administer the lower dose range: 15-30 mg IM loading dose, followed by 15 mg IM every 6 hours 2.
Critical Safety Considerations
High-Risk Populations Requiring Caution
The evidence consistently identifies patients at increased risk for serious adverse events 5:
Renal toxicity risk factors:
- Age ≥60 years
- Compromised fluid status
- Concurrent nephrotoxic drugs (cyclosporine, cisplatin)
- Pre-existing renal insufficiency
GI toxicity risk factors:
- Age ≥60 years
- History of peptic ulcer disease
- Significant alcohol use (≥2 drinks/day)
- Hepatic dysfunction
- Concurrent anticoagulants (warfarin, heparin)
Cardiac toxicity risk factors:
- History of cardiovascular disease
- Concurrent anticoagulation therapy
Absolute Contraindications
Do not use ketorolac in patients with:
- Active or history of GI bleeding
- Cerebrovascular hemorrhage
- Aspirin/NSAID-induced asthma
- Pregnancy or lactation
- Advanced renal or hepatic impairment
- Bleeding disorders or thrombocytopenia 1, 4
Duration and Monitoring
The 5-day maximum duration is non-negotiable. The risk of serious adverse events—particularly GI bleeding, renal impairment, and operative site bleeding—increases substantially with prolonged therapy beyond 5 days 4, 6. The incidence of serious adverse events has declined significantly since dosage guidelines were revised to emphasize lower doses and shorter duration 4, 6.
Required Monitoring
- Baseline: Blood pressure, BUN, creatinine, liver function tests, CBC, fecal occult blood
- During therapy: Monitor for signs of GI bleeding, renal dysfunction, or hypertension
- Repeat labs every 3 months if extended NSAID therapy is considered (though ketorolac should not exceed 5 days) 5
Evidence on Lower Doses
Recent high-quality evidence demonstrates that lower doses of ketorolac (15-20 mg IM) provide equivalent analgesia to higher doses (60 mg IM) with potentially fewer adverse effects 7, 8. A 2023 systematic review found that 15-20 mg doses were non-inferior to 30-60 mg doses for pain relief (mean difference 0.05 mm on 100 mm VAS, 95% CI -4.91 to +5.01 mm) 7. A 2021 military ED study confirmed that 15 mg IM was non-inferior to 60 mg IM, with significantly fewer minor adverse effects (1.8% vs 16.4%, p=0.016) 8.
Clinical implication: Consider starting with 30 mg IM loading dose followed by 15 mg IM every 6 hours, particularly in patients at higher risk for adverse effects, as this provides equivalent analgesia with improved safety profile.
Common Pitfalls to Avoid
- Exceeding 5-day duration: This is the most critical error, substantially increasing risk of serious complications 4, 6
- Using standard adult doses in elderly patients: Always reduce by 50% in patients ≥65 years 1, 3
- Ignoring renal function: Even mild renal impairment warrants dose reduction 5
- Combining with other NSAIDs: Increases toxicity without improving analgesia 5
- Using in perioperative settings without considering bleeding risk: Ketorolac inhibits platelet aggregation and increases bleeding risk 4